| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | CALDER BIOSCIENCES INC | 140 58TH ST | BROOKLYN | NY | 11220-2539 | KINGS | USA | R44AG064107 | An RSV Prefusion F Vaccine that Overcomes Immunosenescence | 000 | 4 | NIH | 7/8/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2022 | CALDER BIOSCIENCES INC | 140 58TH ST | BROOKLYN | NY | 11220-2539 | KINGS | USA | R44AG064107 | An RSV Prefusion F Vaccine that Overcomes Immunosenescence | 000 | 4 | NIH | 4/3/2023 | $0 |
| | 2023 | 2019 | CALDER BIOSCIENCES INC | 140 58TH ST | BROOKLYN | NY | 11220-2539 | KINGS | USA | R43AI140941 | An adjuvant for an RSV prefusion F vaccine that safely protects infants via maternal vaccination | 000 | 2 | NIH | 11/10/2022 | $0 |
| | 2023 | 2019 | CALDER BIOSCIENCES INC. | 140 58TH ST STE 8J | BROOKLYN | NY | 11220-2539 | KINGS | USA | R43AI140941 | An adjuvant for an RSV prefusion F vaccine that safely protects infants via maternal vaccination | 001 | 2 | NIH | 1/6/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $984,686 ) |
| | 2022 | 2022 | CALDER BIOSCIENCES INC. | 140 58TH ST STE 8J | BROOKLYN | NY | 11220-2539 | KINGS | USA | R44AG064107 | An RSV Prefusion F Vaccine that Overcomes Immunosenescence | 001 | 4 | NIH | 3/23/2022 | $984,686 |
| | 2022 | 2019 | CALDER BIOSCIENCES INC | 140 58TH ST | BROOKLYN | NY | 11220-2539 | KINGS | USA | R44AG064107 | An RSV Prefusion F Vaccine that Overcomes Immunosenescence | 000 | 1 | NIH | 2/7/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $989,026 ) |
| | 2021 | 2021 | CALDER BIOSCIENCES INC. | 140 58TH ST STE 8J | BROOKLYN | NY | 11220-2539 | KINGS | USA | R44AG064107 | An RSV Prefusion F Vaccine that Overcomes Immunosenescence | 000 | 3 | NIH | 3/4/2021 | $989,026 |
| | 2021 | 2020 | CALDER BIOSCIENCES INC. | 140 58TH ST STE 8J | BROOKLYN | NY | 11220-2539 | KINGS | USA | R44AG059371 | A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA | 000 | 5 | NIH | 4/14/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,827,206 ) |
| | 2020 | 2020 | CALDER BIOSCIENCES INC. | 140 58TH ST STE 8J | BROOKLYN | NY | 11220-2539 | KINGS | USA | R44AG064107 | An RSV Prefusion F Vaccine that Overcomes Immunosenescence | 001 | 2 | NIH | 2/12/2020 | $939,591 |
| | 2020 | 2020 | CALDER BIOSCIENCES INC. | 140 58TH ST STE 8J | BROOKLYN | NY | 11220-2539 | KINGS | USA | R44AG059371 | A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA | 000 | 5 | NIH | 11/27/2019 | $887,615 |
| | 2020 | 2020 | CALDER BIOSCIENCES INC. | 140 58TH ST STE 8J | BROOKLYN | NY | 11220-2539 | KINGS | USA | R44AG064107 | An RSV Prefusion F Vaccine that Overcomes Immunosenescence | 002 | 2 | NIH | 7/15/2020 | $0 |
| | 2020 | 2019 | CALDER BIOSCIENCES INC. | 140 58TH ST STE 8J | BROOKLYN | NY | 11220-2539 | KINGS | USA | R44AG064107 | An RSV Prefusion F Vaccine that Overcomes Immunosenescence | 000 | 1 | NIH | 2/11/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,073,442 ) |
| | 2019 | 2019 | CALDER BIOSCIENCES INC. | 140 58TH ST STE 8J | BROOKLYN | NY | 11220-2539 | KINGS | USA | R44AG059371 | A Universal Flu Vaccine Based On Conformationally Locked Soluble Headless HA | 003 | 4 | NIH | 8/14/2019 | $374,928 |
| | 2019 | 2019 | CALDER BIOSCIENCES INC. | 140 58TH ST STE 8J | BROOKLYN | NY | 11220-2539 | KINGS | USA | R43AI140941 | An adjuvant for an RSV prefusion F vaccine that safely protects infants via maternal vaccination | 000 | 2 | NIH | 6/21/2019 | $299,955 |
| | 2019 | 2019 | CALDER BIOSCIENCES INC. | 140 58TH ST STE 8J | BROOKLYN | NY | 11220-2539 | KINGS | USA | R44AG064107 | An RSV Prefusion F Vaccine that Overcomes Immunosenescence | 000 | 1 | NIH | 5/10/2019 | $299,740 |
| | 2019 | 2017 | CALDER BIOSCIENCES INC. | 140 58TH ST STE 8J | BROOKLYN | NY | 11220-2539 | KINGS | USA | R44AI112124 | Dityrosine Locked Prefusion F Protein: A Path To A Protective RSV Vaccine | 001 | 5 | NIH | 7/12/2019 | $98,819 |
|
| Issue Date FY: 2018 ( Subtotal = $299,787 ) |
| | 2018 | 2018 | CALDER BIOSCIENCES INC. | 140 58TH ST STE 8J | BROOKLYN | NY | 11220-2539 | KINGS | USA | R43AI140941 | An adjuvant for an RSV prefusion F vaccine that safely protects infants via maternal vaccination | 000 | 1 | NIH | 7/5/2018 | $299,787 |
|
|
